Conflict of Interest in Human Subjects Research

A conflict of interest in human subjects research exists when an investigator’s, institution’s, or IRB member’s financial or personal interest could compromise — or reasonably appear to compromise — the design, conduct, oversight, or reporting of a study involving human participants. It is a narrower, IRB-facing application of the general conflict of interest concept: review here is tied directly to the IRB approval decision itself, not only to institutional disclosure and management.

How this differs from the general institutional COI process

Under the US Public Health Service regulations at 42 CFR Part 50 Subpart F, PHS-funded investigators disclose significant financial interests to their institution, which evaluates and, where warranted, manages them — that institutional disclosure-and-management cycle is covered in full at conflict of interest disclosure. Human-subjects research adds a second layer on top of it: because a financial conflict can distort the risk/benefit judgment, the informed-consent process, or subject recruitment, federal guidance and most institutional Human Research Protection Programs require the IRB itself to see and act on the outcome of that institutional review before the study may proceed, and require any IRB member who personally holds a conflicting interest in a specific protocol to recuse from reviewing or voting on it.

Where COI review enters IRB protocol approval

The 2004 HHS Office for Human Research Protections guidance Financial Relationships and Interests in Research Involving Human Subjects lays out the mechanics most institutions still follow: when an investigator’s disclosure identifies a financial interest that is related to the research, the matter goes to the institution’s conflict-of-interest committee, which develops a management plan (examples include independent monitoring of the consent process, disclosure of the interest to subjects, modification of the study role of the conflicted investigator, or removal from the project). The COI committee communicates that plan to the IRB, and the IRB reviews it alongside the protocol under its general approval criteria (45 CFR 46.111) — specifically whether risks remain minimized and whether the plan is adequate to protect the integrity of informed consent. A study cannot enroll subjects until the IRB has approved both the protocol and the management plan; the IRB’s meeting minutes and protocol file document that the approval is conditioned on the plan being implemented as written.

IRB member conflicts are handled separately

A second, distinct pathway applies when the conflict belongs to someone on the board itself. Under 45 CFR 46.107(e), an IRB member who has a conflicting interest in a specific protocol (for example, serving as co-investigator, or holding a financial stake in the sponsor) may provide information requested by the other members but must not otherwise participate in that protocol’s review or vote on it. This is managed at the point of IRB decision-making, not through the institutional financial-conflict-of-interest (FCOI) disclosure process built for investigator interests under 42 CFR Part 50 Subpart F.

What subjects need to be told

Where a management plan calls for disclosure to participants, the relevant financial relationship is typically summarized in the informed consent document in plain language — naming the type of interest (e.g., equity, royalty, consulting fees) rather than requiring subjects to interpret a compliance filing. NIH’s related notice, NOT-OD-00-040, frames this as a research-objectivity issue for both investigators and IRBs: the point of surfacing the interest is to let a reasonable person, including a prospective subject, judge whether it could have influenced the study’s design or conduct.

Example

A principal investigator on an NIH-funded device trial holds equity above 42 CFR Part 50 Subpart F’s significant-financial-interest threshold in the company manufacturing the device. The institution’s conflict-of-interest committee issues a management plan — an independent data and safety monitor, disclosure of the interest in the consent form, and removal of the PI from the process of obtaining consent — and communicates it to the IRB. The IRB reviews the plan alongside the protocol and documents that approval is conditioned on the plan being implemented; the study cannot enroll subjects until the IRB has approved both the protocol and the management plan.

Example

A voting IRB member is listed as a co-investigator on a study coming before the board at that meeting. Under 45 CFR 46.107(e), the member may answer questions the board asks but must leave the room for deliberation and may not vote on that protocol — the conflict is disclosed and managed at the point of IRB decision-making itself, separately from the institutional FCOI process used for investigator financial interests.

Counter-example

A PI’s only relevant financial relationship is standard per-subject payments from the study sponsor that cover the direct costs of running the trial (staff time, supplies, monitoring visits), with no equity, royalty, or results-contingent bonus. This is disclosed as a funding source but, on its own, does not trigger the significant-financial-interest review and management-plan requirement under 42 CFR Part 50 Subpart F, because there is no personal financial stake tied to the outcome.

References

• PHS regulations on financial conflict of interest, 42 CFR Part 50 Subpart F (2011 revision)
• HHS Office for Human Research Protections, Financial Relationships and Interests in Research Involving Human Subjects: Guidance for Human Subject Protection (2004)
• 45 CFR 46.107(e) (IRB membership and conflicting interests) and 45 CFR 46.111 (criteria for IRB approval)
• NIH Notice NOT-OD-00-040, Financial Conflicts of Interest and Research Objectivity: Issues for Investigators and Institutional Review Boards